MARKET

XGN

XGN

Exagen Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

14.89
+0.63
+4.42%
Opening 11:02 12/02 EST
OPEN
14.49
PREV CLOSE
14.26
HIGH
14.92
LOW
14.49
VOLUME
2.61K
TURNOVER
--
52 WEEK HIGH
29.86
52 WEEK LOW
10.29
MARKET CAP
188.39M
P/E (TTM)
-7.4420
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Exagen Inc. to Participate in December Investor Conferences
SAN DIEGO, Nov. 18, 2020 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, announced today that company management will participate in the following December investor conferences: * Piper Sandler 32nd Annual Virtual Healthcare Conference, November 30 – December 3, 2020 A recorded company presentation will be available via the Piper Sandler conference site from November 23 to December 3, and on the Exagen website at: https://investors.exagen.com/events * Evercore ISI 3rd Annual HealthCONx Conference, December 1-3, 2020 Exagen President and CEO Ron Rocca will participate in a Fireside Chat on Wednesday, December 2, 2020, at 10:30 am EST. A link to the live webcast of the Fireside Chat will be posted to the Exagen website at: https://investors.exagen.com/eventsAbout Exagen Inc.Exagen is dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention. Exagen has developed and is commercializing a portfolio of innovative testing products under its AVISE® brand. Several of these products are based on our proprietary Cell-Bound Complement Activation Products, or CB-CAPs, technology. CB-CAPs assess the activation of the complement system, a biological pathway implicated in systemic lupus erythematosus, or SLE. Exagen’s goal is to enable rheumatologists to improve care for patients through the differential diagnosis, prognosis and monitoring of complex autoimmune and autoimmune-related diseases, including SLE and rheumatoid arthritis, or RA. Exagen’s model of integrating testing products and therapeutics positions Exagen to offer targeted solutions to rheumatologists and, ultimately, better serve patients.  For more information, please visit www.Exagen.com.Investors Westwicke Partners Mike Cavanaugh Mike.Cavanaugh@westwicke.com  646.677.1838Company Exagen Inc. Kamal Adawi, Chief Financial Officer kadawi@exagen.com 760.477.5514
GlobeNewswire · 11/18 21:05
Exagen and GSK partner for 4th straight year, driving greater awareness of challenges facing lupus diagnosis and management
SAN DIEGO, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention, today announced that it has extended its collaboration agreement with GlaxoSmithKline plc (GSK), one of the world’s leading healthcare companies, to raise awareness of the importance of timely diagnosis of systemic lupus erythematosus (SLE), the most common and severe form of lupus. At the center of the program are the proprietary AVISE® laboratory tests, which can facilitate early diagnosis and management of SLE, a complex, incurable autoimmune disease. The details of the agreement are confidential. This extension follows a similar one-year extension that Exagen and GSK entered into last year, and will continue to support the shared goal of helping SLE patients shorten the time to their diagnosis, which is nearly six years on average, and to facilitate improved patient outcomes.Ron Rocca, President and CEO of Exagen shared, “We’re pleased to continue working with GSK, which demonstrates our ability to collaborate with major pharmaceutical companies in a shared commitment to improve patients’ lives. Having access to advanced test result data such as the AVISE® tests can support diagnosis, prognosis, and monitoring of challenging conditions like SLE.”About Exagen Inc.Exagen is dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention. Exagen has developed and is commercializing a portfolio of innovative testing products under its AVISE® brand. Several of these products are based on our proprietary Cell-Bound Complement Activation Products, or CB-CAPs, technology. CB-CAPs assess the activation of the complement system, a biological pathway implicated in systemic lupus erythematosus, or SLE. Exagen’s goal is to enable rheumatologists to improve care for patients through the differential diagnosis, prognosis and monitoring of complex autoimmune and autoimmune-related diseases, including SLE and rheumatoid arthritis, or RA. Exagen’s model of integrating testing products and therapeutics positions Exagen to offer targeted solutions to rheumatologists and, ultimately, better serve patients. For more information, please visit www.Exagen.com.About GSKGSK – a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer. For further information please visit www.gsk.com/about-us.Forward Looking StatementsExagen cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on the company’s current beliefs and expectations. Such forward-looking statements include, but are not limited to, statements regarding the expected benefits or results of Exagen’s collaboration with GSK, and the performance the AVISE® laboratory tests and benefits of the test results data obtained therefrom. The inclusion of forward-looking statements should not be regarded as a representation by Exagen that any of its plans will be achieved. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in Exagen’s business, including, without limitation: the COVID-19 pandemic may continue to adversely affect our business, financial condition and results of operations, including as a result of shutdowns of our facilities and operations as well as those of our suppliers and courier services, impeding patient movement and interruptions to healthcare services causing a decrease in test volumes, disruptions to the supply chain of material needed for our tests, our sales and commercialization activities and our ability to receive specimens and perform or deliver the results from our tests, delays in reimbursement and coverage decisions from Medicare and third-party payors and in interactions with regulatory authorities, and delays in ongoing and planned clinical trials involving our tests; the company’s commercial success depends upon attaining and maintaining significant market acceptance of its testing products and promoted therapeutics among rheumatologists, patients, third-party payers and others in the medical community; the company’s ability to successfully execute on its Dx/Rx strategy, including its promotion efforts for SIMPONI®; third party payers not providing coverage and adequate reimbursement for the company’s testing products or promoted therapeutics; the company’s ability to obtain and maintain intellectual property protection for its testing products; regulatory developments affecting the company’s business; and other risks described in the company’s prior press releases and the Company’s filings with the Securities and Exchange Commission (SEC), including under the heading “Risk Factors” in the company’s Annual Report on Form 10-K and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Exagen undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.Investors Westwicke Partners Mike Cavanaugh Mike.Cavanaugh@westwicke.com 646.677.1838Company Exagen Inc. Kamal Adawi, Chief Financial Officer kadawi@exagen.com 760.477.5514
GlobeNewswire · 11/16 13:25
US$23.75 - That's What Analysts Think Exagen Inc. (NASDAQ:XGN) Is Worth After These Results
Exagen Inc. (NASDAQ:XGN) just released its latest quarterly results and things are looking bullish. Sales crushed...
Simply Wall St. · 11/13 15:19
Exagen Inc. Announces Study to Evaluate Emergence of Autoimmune Diseases After COVID-19 Infection
SAN DIEGO, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, announced today a new study in collaboration with Brigham and Women’s Hospital in Boston, MA. The Brigham is acknowledged internationally for its expertise and innovation in patient care, biomedical research, and educational training programs for physicians, scientists, and health care professionals. As viruses are implicated in the development of autoimmune diseases, there is the need to understand the effects of the current COVID-19 pandemic on the development of rheumatic autoimmune diseases. This study will evaluate the incidence and risk factors for onset of rheumatic autoimmune diseases in people who recovered from COVID-19.Positive polymerase chain reaction (PCR)-confirmed COVID-19 patients from the Brigham will be invited to partake in the year-long evaluation. Patients will be categorized by COVID-19 severity: mild (outpatient), moderate (inpatient, not ICU), and severe (ICU). Patients who elect to participate will be assessed with two validated questionnaires and tested using AVISE® biomarkers to investigate the new onset of rheumatic disease symptoms and autoantibodies in the 3 months to 1 year following onset of COVID-19.“True incidence rates and risk factors associated with autoimmune and rheumatic diseases arising after COVID-19 are not known. We are proud to work with Brigham and Women’s Hospital, particularly their strong rheumatic disease epidemiology research team, to examine this further,” said Ron Rocca, President and CEO of Exagen.About Exagen Inc.Exagen is dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention. Exagen has developed and is commercializing a portfolio of innovative testing products under its AVISE® brand. Several of these products are based on our proprietary Cell-Bound Complement Activation Products, or CB-CAPs, technology. CB-CAPs assess the activation of the complement system, a biological pathway implicated in systemic lupus erythematosus, or SLE. Exagen’s goal is to enable rheumatologists to improve care for patients through the differential diagnosis, prognosis and monitoring of complex autoimmune and autoimmune-related diseases, including SLE and rheumatoid arthritis, or RA. Exagen’s model of integrating testing products and therapeutics positions Exagen to offer targeted solutions to rheumatologists and, ultimately, better serve patients. For more information, please visit www.Exagen.com.Forward Looking StatementsExagen cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on the company’s current beliefs and expectations. Such forward-looking statements include, but are not limited to, statements regarding the study in collaboration with the Brigham and any potential findings related to the incidence and risk factors for consent of rheumatic autoimmune diseases in people who recovered from COVID-19. The inclusion of forward-looking statements should not be regarded as a representation by Exagen that any of its plans will be achieved. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in Exagen’s business, including, without limitation: the COVID-19 pandemic may continue to adversely affect our business, financial condition and results of operations, including as a result of shutdowns of our facilities and operations as well as those of our suppliers and courier services, impeding patient movement and interruptions to healthcare services causing a decrease in test volumes, disruptions to the supply chain of material needed for our tests, our sales and commercialization activities and our ability to receive specimens and perform or deliver the results from our tests, delays in reimbursement and coverage decisions from Medicare and third-party payors and in interactions with regulatory authorities, and delays in ongoing and planned clinical trials involving our tests; the company’s commercial success depends upon attaining and maintaining significant market acceptance of its testing products and promoted therapeutics among rheumatologists, patients, third-party payers and others in the medical community; the company’s ability to successfully execute on its Dx/Rx strategy, including its promotion efforts for SIMPONI®; third party payers not providing coverage and adequate reimbursement for the company’s testing products or promoted therapeutics; the company’s ability to obtain and maintain intellectual property protection for its testing products; regulatory developments affecting the company’s business; and other risks described in the company’s prior press releases and the Company’s filings with the Securities and Exchange Commission (SEC), including under the heading “Risk Factors” in the company’s Annual Report on Form 10-K and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Exagen undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.Investors Westwicke Partners Mike Cavanaugh Mike.Cavanaugh@westwicke.com  646.677.1838Company Exagen Inc. Kamal Adawi, Chief Financial Officer kadawi@exagen.com 760.477.5514
GlobeNewswire · 11/02 13:25
Exagen to Announce Third Quarter Financial Results on November 10, 2020
SAN DIEGO, Oct. 27, 2020 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, today announced that it will release financial results for the quarter ended September 30, 2020 after the market close on Tuesday, November 10, 2020. Ron Rocca, President and Chief Executive Officer, and Kamal Adawi, Chief Financial Officer, will host a conference call to review the Company’s results at 4:30 PM Eastern Time (1:30 PM Pacific Time). Interested parties may access the conference call by dialing (877) 407-3982 (U.S.) or (201) 493-6780 (international). Participants wishing to access the call via webcast should use the link posted on the Exagen investor relations website at https://investors.exagen.com/.A replay of the conference call will be available until Tuesday, November 17, 2020 at 11:59 PM Eastern Time (8:59 PM Pacific Time). Interested parties may access the replay of the conference call by dialing (844) 512-2921 (U.S.) or (412) 317-6671 (international) using passcode 13711892. Additionally, a recording of the webcast will be available using the link on the Exagen investor relations website approximately 30 minutes after the call concludes.About Exagen Inc.Exagen is dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention. Exagen has developed and is commercializing a portfolio of innovative testing products under its AVISE® brand, several of which are based on our proprietary Cell-Bound Complement Activation Products, or CB-CAPs, technology. Exagen’s goal is to enable rheumatologists to improve care for patients through the differential diagnosis, prognosis and monitoring of complex autoimmune and autoimmune-related diseases, including SLE and rheumatoid arthritis.CONTACTS:InvestorsWestwicke Partners Mike Cavanaugh Mike.Cavanaugh@westwicke.com 646.677.1838Company ContactExagen Inc. Kamal Adawi, Chief Financial Officer KAdawi@exagen.com 760.477.5514
GlobeNewswire · 10/27 21:05
Exagen Showcases Six Scientific Presentations at ACRs First Virtual Annual Meeting in November 2020
SAN DIEGO, Oct. 21, 2020 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, announced today it will be presenting new scientific research at the American College of Rheumatology’s (ACR) first virtual annual meeting, ACR Convergence 2020. The event is being held online from November 5-9, 2020. Exagen’s Chief Scientific Officer, Anja Kammesheidt, shared, “Exagen is honored to have had the opportunity to partner with such great collaborators on this year’s abstracts. Our clinical research and development teams are committed to advancing the understanding of the role of cell-bound complement activation products (CB-CAPs) in lupus. We are pleased to be sharing these data at this year’s virtual ACR event.”Below is the list of accepted abstracts along with links to each:Saturday, November 7thPoster Presentation | Presented by Michelle Petri, MD | Abstract 0857 Title: Agreement of Hydroxychloroquine Blood Levels Between a University and Commercial Laboratory Session Title: SLE – Treatment Poster I Session Time: 9:00 am – 11:00 am ESTSunday, November 8thOral Presentation | Presented by Yevgeniya Gartshteyn, MD | Abstract 1510 Title: Platelet-bound C4d is Associated with Platelet Activation and Arterial Thrombotic Events Session Title: SLE – Diagnosis, Manifestations, & Outcomes II: Bench to Bedside (1507–1511) Session Time: 3:00 pm – 3:50 pm ESTOral Presentation | Presented by Michelle Petri, MD | Abstract 1513 Title: Role of Platelet C4d in Thrombosis and Lupus Nephritis Session Title: SLE – Diagnosis, Manifestations, & Outcomes III: Lupus Nephritis (1512–1516) Session Time: 4:00 pm – 4:50 pm ESTMonday, November 9th Poster Presentation | Presented by Yevgeniya Gartshteyn, MD | Abstract 1792 Title: Platelet-bound C4d is Associated with an Increased Risk of Arterial and Venous Thromboses in SLE Session Title: SLE – Diagnosis, Manifestations, & Outcomes Poster III: Bench to Bedside Session Time: 9:00 am – 11:00 am ESTPoster Presentation | Presented by Rosalind Ramsey-Goldman, MD | Abstract 1797 Title: A Multianalyte Assay Panel (MAP) With Algorithm Containing Cell-Bound Complement Activation Products (CB-CAPs) Is Superior to Anti-dsDNA And Low Serum Complement Levels in Predicting Transition of Probable Lupus to ACR Classified Lupus Within 2 Years Session Title: SLE – Diagnosis, Manifestations, & Outcomes Poster III: Bench to Bedside Session Time: 9:00 am – 11:00 am ESTPoster Presentation | Presented by Jill Buyon, MD | Abstract 1808 Title: Erythrocyte Complement Receptor 1 (ECR1) and Erythrocyte Bound C4d (EC4d) Associate with Adverse Pregnancy Outcomes and Preeclampsia in Pregnant Women with Systemic Lupus Erythematosus (SLE) Session Title: SLE – Diagnosis, Manifestations, & Outcomes Poster III: Bench to Bedside Session Time: 9:00 am – 11:00 am EST* Abstracts will remain live until March 11, 2021About Exagen Inc.Exagen is dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention. Exagen has developed and is commercializing a portfolio of innovative testing products under its AVISE® brand. Several of these products are based on our proprietary Cell-Bound Complement Activation Products, or CB-CAPs, technology. CB-CAPs assess the activation of the complement system, a biological pathway implicated in systemic lupus erythematosus, or SLE. Exagen’s goal is to enable rheumatologists to improve care for patients through the differential diagnosis, prognosis and monitoring of complex autoimmune and autoimmune-related diseases, including SLE and rheumatoid arthritis, or RA. Exagen’s model of integrating testing products and therapeutics positions Exagen to offer targeted solutions to rheumatologists and, ultimately, better serve patients.  For more information, please visit www.Exagen.com Forward Looking StatementsExagen cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on the company’s current beliefs and expectations. Such forward-looking statements include, but are not limited to, statements regarding the scientific abstracts for presentation at ACR Annual Conference and the potential to lead to increased adoption of any AVISE® test.  The inclusion of forward-looking statements should not be regarded as a representation by Exagen that any of its plans will be achieved. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in Exagen’s business, including, without limitation: the COVID-19 pandemic may continue to adversely affect our business, financial condition and results of operations, Exagen’s commercial success depends upon attaining and maintaining significant market acceptance of its testing products and promoted therapeutics among rheumatologists, patients, third-party payers and others in the medical community; third party payers not providing coverage and adequate reimbursement for the company’s testing products or promoted therapeutics; the company’s ability to obtain and maintain intellectual property protection for its testing products; regulatory developments affecting the company’s business; risks associated with maintaining third-party partnerships and Exagen’s performance thereunder; and other risks described in the company’s prior press releases and the Company’s filings with the Securities and Exchange Commission (SEC), including under the heading “Risk Factors” in the company’s Annual Report on Form 10-K and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Exagen undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.Investors Westwicke Partners Mike Cavanaugh Mike.Cavanaugh@westwicke.com 646.677.1838Company Exagen Inc. Kamal Adawi, Chief Financial Officer kadawi@exagen.com 760.477.5514
GlobeNewswire · 10/21 21:05
Exagen Showcases Six Scientific Presentations At ACR's First Virtual Annual Meeting Nov. 5-9, 2020
SAN DIEGO, Oct. 21, 2020 (GLOBE NEWSWIRE) -- Exagen Inc. (NASDAQ:XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, announced
Benzinga · 10/21 20:10
Exagen points to positive economic benefits of Avise
Exagen (XGN) says a new study supports the economic benefits of Avise Lupus testing. Key advancements and findings include that over the four-year time horizon Avise Lupus demonstrated an estimated
Seekingalpha · 10/12 20:14
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of XGN. Analyze the recent business situations of Exagen Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average XGN stock price target is 23.75 with a high estimate of 32.00 and a low estimate of 20.00.
EPS
Institutional Holdings
Institutions: 42
Institutional Holdings: 4.28M
% Owned: 33.81%
Shares Outstanding: 12.65M
TypeInstitutionsShares
Increased
9
590.06K
New
4
249.95K
Decreased
19
253.41K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Medical Equipment, Supplies & Distribution
-0.28%
Healthcare Equipment & Supplies
-0.15%
Key Executives
Chairman/Independent Director
Brian Birk
President/Chief Executive Officer/Director
Fortunato Rocca
Chief Financial Officer/Secretary
Kamal Adawi
Vice President - Finance
Mark Hazeltine
Chief Scientific Officer
Anja Kammesheidt
Other
Debra Zack
Independent Director
Chet Burrell
Independent Director
Jeffrey Elliott
Independent Director
Wendy Johnson
Independent Director
Tina Nova
Independent Director
Ebetuel Pallares
Independent Director
Bruce Robertson
Independent Director
James Tullis
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About XGN
Exagen Inc. is a commercial-stage life sciences company. The Company offers physicians testing for patients and healthcare providers in diagnosis, prognosis and monitoring of autoimmune conditions. Its diagnostic tests include AVISE connective tissue disease (CTD), AVISE Lupus and AVISE antiphospholipid syndrome (APS). Its prognostic tests include AVISE systemic lupus erythematosus (SLE) Prognostic, AVISE Platelet-bound C4d (PC4d) and AVISE Anti- carbamylated proteins (CarP). Its monitoring tests include AVISE SLE Monitor, AVISE methotrexate (MTX) and AVISE hydroxychloroquine (HCQ).
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Exagen Inc stock information, including NASDAQ:XGN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, XGN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading XGN stock methods without spending real money on the virtual paper trading platform.